Enlivex Therapeutics Ltd (ENLV) - Total Assets
Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) holds total assets worth ILA20.94 Million ILA (≈ $56.13K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Enlivex Therapeutics Ltd (ENLV) net assets for net asset value and shareholders' equity analysis.
Enlivex Therapeutics Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Enlivex Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Enlivex Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Enlivex Therapeutics Ltd's total assets of ILA20.94 Million consist of 93.9% current assets and 6.1% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 11.9% |
| Accounts Receivable | ILA1.42 Million | 5.1% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Enlivex Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Enlivex Therapeutics Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enlivex Therapeutics Ltd's current assets represent 93.9% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2024, down from 93.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 5.1% of total assets.
Enlivex Therapeutics Ltd Competitors by Total Assets
Key competitors of Enlivex Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK
|
USA | $59.55 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $460.00 Million |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥5.19 Billion |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $424.43 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Enlivex Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.43 | 9.71 | 8.72 |
| Quick Ratio | 6.43 | 9.71 | 8.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA16.47 Million | ILA24.32 Million | ILA33.75 Million |
Enlivex Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Enlivex Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.25 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -24.8% |
| Total Assets | ILA27.69 Million |
| Market Capitalization | $458.60K USD |
Valuation Analysis
Below Book Valuation: The market values Enlivex Therapeutics Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enlivex Therapeutics Ltd's assets decreased by 24.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual total assets of Enlivex Therapeutics Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA27.69 Million ≈ $74.23K |
-24.83% |
| 2023-12-31 | ILA36.83 Million ≈ $98.74K |
-45.55% |
| 2022-12-31 | ILA67.64 Million ≈ $181.35K |
-28.91% |
| 2021-12-31 | ILA95.15 Million ≈ $255.08K |
+135.75% |
| 2020-12-31 | ILA40.36 Million ≈ $108.20K |
+129.83% |
| 2019-12-31 | ILA17.56 Million ≈ $47.08K |
+59.14% |
| 2018-12-31 | ILA11.03 Million ≈ $29.58K |
+204.64% |
| 2017-12-31 | ILA3.62 Million ≈ $9.71K |
-65.93% |
| 2016-12-31 | ILA10.63 Million ≈ $28.50K |
-48.19% |
| 2015-12-31 | ILA20.52 Million ≈ $55.00K |
-37.74% |
| 2014-12-31 | ILA32.95 Million ≈ $88.35K |
+479.56% |
| 2013-12-31 | ILA5.69 Million ≈ $15.24K |
+3544.87% |
| 2012-12-31 | ILA156.00K ≈ $418.23 |
-- |
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more